Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 3—March 2015
Research

Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010

Adoración Navarro-TornéComments to Author , Joana Gomes Dias, Frantiska Hruba, Pier Luigi Lopalco, Lucia Pastore-Celentano, Andrew J. Amato Gauci, and Invasive Pneumococcal Disease Study Group
Author affiliations: Universidad Autónoma de Barcelona, Barcelona, Spain (A. Navarro-Torné); European Centre for Disease Prevention and Control, Stockholm, Sweden (A. Navarro-Torné, J. Gomes Dias, F. Hruba, P.L. Lopalco, L. Pastore-Celentano, A.J. Amato Gauci)

Main Article

Table 6

Characteristics of national pneumococcal vaccination programs in European Union/European Economic Area countries, 2010*

Country Date of PCV7 introduction Scope of PCV vaccination program Immunization schedule Dose
 Vaccine coverage† Year of measurement
First, mo Second, mo Third, mo Fourth, mo
Austria 2004 Jul Universal 3+1 dose 3 5 7 12–24 NA NA
Belgium 2005 Jan Universal 2+1 dose 2 4 12 97 2010
Bulgaria 2010 Apr Universal 3+1 dose/2+1 dose 2 3 4 12 NA NA
Cyprus 2008 Aug Universal 3+1 dose 2 4 6 12–15 NA NA
Czech Republic 2010 Jan Risk-based 3+1 dose 2 4 6 18 86.3 2010
Denmark 2007 Oct Universal 2+1 dose 3 5 12 85 2010
Estonia NA NA not decided NA NA NA NA NA NA
Finland 2009 Jan Risk-based 2+1 dose 3 5 12 NA NA
France 2006 Jun Universal 2+1 dose 2 4 12 81 2008
Germany 2006 Jul Universal 3+1 dose 2 3 4 11–14 52.9 2010
Greece 2006 Jan Universal 3+1 dose 2 4 6 12–15 NA NA
Hungary 2008 Oct Universal 2+1 dose 2 4 15 81.1 2009
Iceland 2006 Dec Risk-based 2+1 dose 3 5 12 NA NA
Ireland 2002 Oct Universal 2+1 dose 2 6 12 89 2009
Italy 2005 May Universal/risk- based 2+1 dose 3 5 11 55 2008
Latvia 2010 Jan Universal 3+1 dose 2 4 6 12–15 51 2010
Lithuania NA NA 3+1 dose 2 4 6 24 NA NA
Luxembourg 2003 Feb Universal 3+1 dose 2 3 4 12–15 86 2010
Malta 2007 Jan Risk-based 3+1 dose 2 4 13 None NA NA
Netherlands 2006 Jun Universal 3+1 dose 2 3 4 11 94 2009
Norway 2006 Jul Universal 2+1 dose 3 5 12 90 2009
Poland 2008 May Risk-based 3+1 dose/2+1 dose NA NA NA NA 1.70 2008
Portugal 2010 Jun Risk-based 2+1 dose 2 4 12–15 52 2009
Romania‡ 3+1 dose 2 4 6 15–18
Slovakia§ 2006 Jan Risk-based 2+1 dose 2 4 10 99.2 2009
Slovenia 2005 Sep Risk-based 3+1 dose 2-3 4 6 24 NA NA
Spain¶ 2001 Jun Risk-based 3+1 dose 2 4 6 15 NA NA
Sweden 2009 Jan Universal 2+1 dose 3 5 12 NA NA
United Kingdom 2006 Sep Universal 2+1 dose 2 4 13 90 2010

*NA, not available; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV. Blank cells indicate not applicable.
†Sources: Vaccine European New Integrated Collaboration Effort II project and World Health Organization estimates of PCV7 coverage.
‡PCV7 was registered in September 2007 for voluntary use on a private basis.
§Universal as of April 2008.
¶Universal introduction in the autonomous region of Madrid in November 2006.

Main Article

1Members of the Invasive Pneumococcal Disease Study Group who contributed data are listed at the end of this article.

Page created: April 16, 2015
Page updated: April 16, 2015
Page reviewed: April 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external